0000899243-20-034529.txt : 20201218 0000899243-20-034529.hdr.sgml : 20201218 20201218180622 ACCESSION NUMBER: 0000899243-20-034529 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201208 FILED AS OF DATE: 20201218 DATE AS OF CHANGE: 20201218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Machatha Stephen CENTRAL INDEX KEY: 0001836354 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 201401847 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-12-08 0 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001836354 Machatha Stephen C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE, SUITE 320 LEXINGTON MA 02421 0 1 0 0 Chief Development Officer Common Stock 20091 D Common Stock 211 I See Footnote Employee Stock Option (Right to Buy) 4.60 2026-04-05 Common Stock 35000 D Employee Stock Option (Right to Buy) 5.25 2027-03-09 Common Stock 26200 D Employee Stock Option (Right to Buy) 8.35 2028-02-28 Common Stock 45573 D Employee Stock Option (Right to Buy) 8.05 2029-03-04 Common Stock 32000 D Employee Stock Option (Right to Buy) 8.05 2029-03-04 Common Stock 31000 D Employee Stock Option (Right to Buy) 3.78 2030-03-01 Common Stock 135560 D These shares are held directly by Dr. Machatha's spouse. Dr. Machatha disclaims beneficial ownership over these shares for purposes of Section 16 or for any other purposes. The shares subject to this option shall vest over 4 years of service following January 8, 2016, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2017. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2018. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2019. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020. /s/ Stephen Machatha 2020-12-18